Verastem (VSTM) was granted accelerated approval from the US Food and Drug Administration for the Avmapki Fakzynja Co-pack to treat patients with KRAS-mutated, recurrent low-grade serous ovarian cancer, according to a statement from the regulator.
The efficacy of the drug combination of avutometinib and defactinib was assessed in a trial of 57 adult patients who had received prior systemic therapy, the FDA said.
The overall response rate and duration of response range recorded during the trial were 44% and between 3.3 months and 31.1 months, according to a statement.
There were several common adverse reactions observed, including nausea, rash, diarrhea, edema, abdominal pain, pruritus, visual impairment, cough, and urinary tract infections, the regulator said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。